Monoclonal Antibodies Addressed to Factors of Signalization in Keloid Scars: Opportunities and Areas of Action.
| Autor: | Moreno Pizarro E; Medicine, University of Guanajuato, León, MEX., Morales Valencia E; Surgery, Hospital Regional de Alta Especialidad del Bajío, León, MEX., Pérez Cuéllar A; Orthopedics and Traumatology, General Hospital of León, León, MEX.; Orthopedics and Traumatology, Medica Campestre Hospital, León, MEX., Acuña Pinzon C; General Surgery, Hospital Regional de Alta Especialidad del Bajío, León, MEX., Serrano Padilla AE; Medicine, University of Guanajuato, León, MEX. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2020 Jun 28; Vol. 12 (6), pp. e8894. Date of Electronic Publication: 2020 Jun 28. |
| DOI: | 10.7759/cureus.8894 |
| Abstrakt: | The advance of technology has made possible the use of new techniques within medicine for the treatment of diseases; monoclonal antibodies are a clear example of this. Keloid scars are one of the most difficult pathologies to treat due to the high percentage of recidivism, formed by the growth of a scar with benign fibrous tissue in genetically predisposed individuals, resulting from a process of inflammation and abnormal scarring. Monoclonal antibodies, being a line of treatment that has increased over the years, can show a new frontier in the treatment of them by focusing on the signaling that causes it. We review the literature on the signaling mechanisms of keloid scars and the possible monoclonal approach. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2020, Moreno Pizarro et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|